anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The role of lifestyle factors and their relative contributions to the development and mortality of cardio-renal-metabolic multimorbidity (CRMM) remains unclear.
METHODS: A study was conducted with 357,554 UK Biobank participants. CRMM was defined as the coexistence of two or three cardio-renal-metabolic diseases (CRMDs), including cardiovascular disease (CVD), type 2 diabetes (T2D) and chronic kidney disease (CKD). The prospective study examined the associations of individual and combined lifestyle scores (diet, alcohol consumption, smoking, physical activity, sedentary behavior, sleep duration and social connection) with longitudinal progression from healthy to first cardio-renal-metabolic disease (FCRMD), then to CRMM, and ultimately to death, using a multistate model. Subsequently, quantile G-computation was employed to assess the relative contribution of each lifestyle factor.
RESULTS: During a median follow-up of 13.62 years, lifestyle played crucial role in all transitions from healthy to FCRMD, then to CRMM, and ultimately to death. The hazard ratios (95% CIs) per score increase were 0.91 (0.90, 0.91) and 0.90 (0.89, 0.91) for healthy to FCRMD, and for FCRMD to CRMM, and 0.84 (0.83, 0.86), 0.87 (0.86, 0.89), and 0.90 (0.88, 0.93) for mortality risk from healthy, FCRMD, and CRMM, respectively. Among the seven factors, smoking status contributed to high proportions for the whole disease progression, accounting for 19.88-38.10%. High-risk diet contributed the largest proportion to the risk of transition from FCRMD to CRMM, with 22.53%. Less-frequent social connection contributed the largest proportion to the risk of transition from FCRMD to death, with 28.81%. When we further consider the disease-specific transitions, we find that lifestyle scores had slightly stronger associations with development to T2D than to CVD or CKD.
CONCLUSIONS: Our study indicates that a healthy lifestyle may have a protective effect throughout the longitudinal progression of CRMM, informing more effective management and treatment. Smoking status, diet, and social connection played pivotal roles in specific disease transitions.
OBJECTIVE: To investigate markers of systemic inflammation and the effect of thyroid dysfunction on these parameters in patients with Hashimoto's thyroiditis (HT).
METHODS: Patients with HT and volunteer healthy individuals admitted to the general surgery outpatient clinic between January 2020 and June 2023 were enrolled into the study. Patients with HT were divided into euthyroid, hypothyroid, and hyperthyroid subgroups. All participant data were retrospectively extracted from the hospital database.
RESULTS: A total of 268 patients (euthyroid, n = 131; hypothyroid, n = 83; and hyperthyroid, n = 54) and 124 controls were included. The platelet-to-lymphocyte ratio was lower in the euthyroid group versus control group, and the neutrophil-to-lymphocyte ratio was lower in controls than the three patient subgroups. Euthyroid and hypothyroid patients with HT exhibited a higher systemic inflammation index than the control group. The pan-immune inflammation index was lower in controls than in euthyroid, hypothyroid, and hyperthyroid patients with HT. In patients with HT, inflammation markers did not significantly differ between subgroups.
CONCLUSIONS: Markers of systemic inflammation provide meaningful and reliable information in patients with HT, but do not differentiate between euthyroid, hypothyroid, or hyperthyroid patients.
Polyploidy is widely recognized as an important speciation mechanism because it isolates tetraploids from their diploid progenitors. Polyploidy also provides new genetic material that may facilitate adaptive evolution. However, new mutations are more likely to arise after a neopolyploid has already successfully invaded a population. Thus, the role of adaptive forces in establishing a polyploid remains unclear. One solution to this apparent paradox may lie in the capacity of polyploids to suppress recombination among preexisting locally adapted alleles. The local adaptation mechanism requires that spatially heterogeneous selection acts on multiple loci and that gene flow introduces maladapted alleles to the population where the polyploid forms. The mechanism requires neither strong genetic drift nor any intrinsic benefit of genome doubling and can accommodate any mode of gene action. A unique prediction of the mechanism is that adaptive alleles should predate polyploidization, a pattern consistent with observations from a few well-studied polyploids. The mechanism is also consistent with the coexistence of both diploid and tetraploid cytotypes, fitness heterogeneity among independently derived polyploids, and the prevalence of outcrossing among older polyploids. The local adaptation mechanism also makes novel predictions about circumstances favoring polyploid invasions that can be tested using molecular genetic or comparative approaches.
PURPOSE:To remove a substance acting as an anticompliment from a solution of unrefined immunoglobulin, in high efficiency, without deactivating the immunoglobulin useful for the treatment of infectious diseases, by adding alumina, silicic acid, etc. to the crude solution, stirring the mixture, and separating the alumina, etc. from the mixture. CONSTITUTION:An immunoglobulin solution containing a substance acting as an anticompliment is added with alumina, silicic acid and aluminum silicate, stirred preferably at 15-37 deg.C for 1-2hr, and the alumina, silicic acid, etc. are separated from the mixture by filtration to achieve the removal of the anticomplimental component from the solution. The amount of the alumina, silicic acid, etc. is preferably 5-30% of the immunoglobulin. Especially, a product having an anticompliment value (CH50) of <=20 units can be prepared at a yield of >=85% by using the powder of immunoglobulin obtained by the Cohn's ethanol fractionation method.
BACKGROUND: Cerebral ischemia (CI), ranking as the second leading global cause of death, is frequently treated by reestablishing blood flow and oxygenation. Paradoxically, this reperfusion can intensify tissue damage, leading to CI-reperfusion injury. This research sought to uncover biomarkers pertaining to protein processing in the endoplasmic reticulum (PER) during CI-reperfusion injury.
METHODS: We utilized the Gene Expression Omnibus (GEO) dataset GSE163614 to discern differentially expressed genes (DEGs) and single out PER-related DEGs. The functions and pathways of these PER-related DEGs were identified via Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Core genes were pinpointed through protein-protein interaction (PPI) networks. Subsequent to this, genes with diagnostic relevance were distinguished using external validation datasets. A single-sample gene-set enrichment analysis (ssGSEA) was undertaken to pinpoint genes with strong associations to hypoxia and apoptosis, suggesting their potential roles as primary inducers of apoptosis in hypoxic conditions during ischemia-reperfusion injuries.
RESULTS: Our study demonstrated that PER-related genes, specifically ADCY5, CAMK2A, PLCB1, NTRK2, and DLG4, were markedly down-regulated in models, exhibiting a robust association with hypoxia and apoptosis.
CONCLUSION: The data indicates that ADCY5, CAMK2A, PLCB1, NTRK2, and DLG4 could be pivotal genes responsible for triggering apoptosis in hypoxic environments during CI-reperfusion injury.
This formula is related to strengthening gastrointestinal digestion, improving gastrointestinal function and immune system, avoiding gastroesophageal reflux, anti-oxidation, anti-allergic, regulating acid-base balance in the body and improving constipation. Raw materials are selected according to the research results of international journal papers and analyzed through liquid chromatography tandem mass spectrometry (LC/MS/MS). By comparing with single standard products, the concentration (%) of functional components are determined. The raw materials are proportioned with three proportions selected for verification by cell experiments. According to the experimental results, the best formula ratio is established. Fucoidan used in the present invention is a natural extract, without chemical residue problem after taking, and no restriction on the taking time.
PURPOSE:To obtain a new peptide having functions to activate the cell growth and a cell growth activator, containing the peptide and having enhanced effects. CONSTITUTION:This peptide has any of amino acid sequences expressed by formulas I to VII or its derivative. This cell growth activator is obtained by blending the peptide, its derivative or a mixture thereof with an epidermal growth factor as active ingredients and more effective than a medicine of the epidermal growth factor alone. Both the ingredients in the activator are contained at concentrations of the peptide within the range of 0.1mug to 100mg/g peptide and the epidermal growth factor within the range of 0.01ng to 10mug/g. The peptide is obtained by hydrolyzing lactoferrins as a raw material with an acid or an enzyme and isolating the peptide from the resultant hydrolyzate. For example, the peptide is prepared by hydrolyzing a bovine lactoferrin with pepsin, dissolving the resultant hydrolyzate in water and isolating the peptide based on a linear gradient obtained from a mixture of a 0.5% aqueous solution of trifluoroacetic acid with a 90% aqueous solution of acetonitrile containing 0.041% trifluoroacetic acid at different concentrations of both the solutions using a column filled with ODS120-T(R) (manufactured by Tosoh Corp.).
The invention relates to a pancreatic cancer JAK2 and STAT3 dual-targeting inhibitor containing a phenoxy acethydrazide compound and application thereof, wherein the dual-targeting inhibitor comprises a compound containing a phenoxy acethydrazide structure. Dual targeted inhibitors include pharmaceutically acceptable salts. Application of the phenoxy acethydrazide compound-containing pancreatic cancer JAK2 and STAT3 dual-targeting inhibitor in preparing medicaments for treating pancreatic cancer. By inhibiting tumor proliferation, migration invasion, angiogenesis, epithelial-to-mesenchymal transition; blocking the cell cycle; promoting apoptosis in treating pancreatic cancer. The medicinal preparation of the medicinal composition comprises tablets, capsules, syrup, suspending agent and injection. A medicament for treating pancreatic cancer, comprising a pancreatic cancer JAK2 and STAT3 dual-targeting inhibitor comprising a phenoxy acetyl hydrazine compound and a pharmaceutically acceptable carrier. The invention has the beneficial effects that: the kit has a good inhibition effect on pancreatic cancer JAK2 and STAT3, and experimental results show that the kit has a good inhibition effect, a wider application prospect and good safety.
A dry, free-flowing vitamin preparation, suitable particularly for mixture with the usual cattle and poultry feeds in that the vitamin content after a period of storage in the presence of mineral constituents is at least 80 per cent of the vitamin content after storage for the same period without mineral constituents, is made by the spraying into warm gas of a dispersion of oil containing Vitamin A, Vitamin D, or both vitamins in an aqueous liquid containing gelatine and a water-soluble carbohydrate, e.g. a hexose or disaccharide, particularly glucose or lactose.  The preparation preferably contains more than 20 I.U./g. of Vitamin A and/or more than 10 I.U./g. of Vitamin D.  The aqueous liquid may contain other proteins such as lactalbumin or blood albumen and may contain pectin, agar-agar, carragheen, an alginate, or a cellulose derivative such as carboxymethylcellulose or methyl cellulose. The aqueous liquid may contain substances which combine with ions of metals catalysing oxidation of vitamins or which otherwise deter oxidation of vitamins or which otherwise deter oxidation of vitamins, e.g. phospholipids such as lecithin, gallic acid and esters thereof, phosphoric, pyrophosphoric, citric, thiopropionic and ascorbic acids, alkali metal sulphides, sorbitol, tocopherols, nordihydroguaiaretic acid, guaiacum resin, tertiary butyl hydroxyanisole, hydroquinone, polyphenols.  The dispersion sprayed may contain 50 per cent of solids, and is preferably of viscosity not more than 70 DEG  Engler at 55 DEG  C.  The test mineral mixture contains ground and washed chalk, gelatine-free bone flour, calcium phosphate, iodized kitchen salt, and magnesium, ferrous, copper, manganese and cobalt sulphates.ALSO:A dry, free-flowing vitamin preparation which after storage in the presence of mineral constituents retains at least 80 per cent of the vitamin content after storage for the same period without mineral constituents is made by the spraying into warm gas of a dispersion of oil containing vitamin A, vitamin D, or both vitamins in an aqueous liquid containing gelatine and a water-soluble carbohydrate, e.g. a hexose or disaccharide, particularly glucose or lactose.  The preparation preferably contains more than 20 I. U./g. of vitamin A and/or more than 10 I.U./g. of vitamin D.  The aqueous liquid may contain other proteins such as lactalbumin or blood albumen and may contain pectin, agar-agar, carragheen, an alginate, or a cellulose derivative such as carboxymethyl-cellulose or methyl cellulose. The aqueous liquid may contain substances which combine with ions of metals catalysing oxidation of vitamins, e.g. phospholipids such as lecithin, gallic acid and esters thereof, phosphoric, pyrophorphoric, citric, thiopropionic and ascorbic acids, alkali metal sulphides, sorbitol, tocopherols, nordihydroguaiaretic acid, guaiacum resin, tertiary butyl hydroxyanisole, hydroquinone, polyphenols.  The dispersion sprayed may contain 50 per cent of solids, and is preferably of viscosity not more than 70 degrees Engler at 55 DEG C.
Ageing myocardium undergoes structural and functional changes characterized by progressive cardiomyocyte hypertrophy, interstitial fibrosis and inflammation ultimately leading to diastolic and systolic dysfunction. Whilst most focus has been placed on established risk factors such as dyslipidaemia, hypertension and obesity in accelerating cardiac ageing, 4 a potential role for amino acids has received little attention. Here the inventors show that increased phenylalanine (PA) levels induced in vitro cytosolic oxidative stress and senescence whilst in vivo led to senile-like cardiac deterioration in young mice. Moreover, they demonstrated that hepatic PA catabolism declined with age in a p21-dependent manner, whilst p21 deficiency prevented age-related cardiac dysfunction. Finally, the inventors found that Pah cofactor BH4 reversed the age-related rise in plasma PA levels and senile cardiac alterations. These observations have immediate implications for promoting cardiac health and healthspan and suggest that phenylalanine can be used as a biomarker and biotarget of cardiac dysfunction.
The proposed study is a prospective, randomized controlled, single-center laboratory study involving 10 healthy volunteers. Once the potential participant has cleared the screening, consented to the study procedures, completed the medical interview, and laboratory blood testing, the subject will undergo two serial mobilization events. The scheduling of the mobilization events will be varied across the 10 participants to counter sequencing effects of the mobilization events. 5 healthy donors will be administered standard filgrastim mobilization regimen of 10 mcg/kg per day for 4 days. This will be followed by a standard pegfilgrastim mobilization regimen consisting of one 6 mg injection separated by 8 weeks for 5 of the participants. The other 5 healthy donors will receive the reverse order of the pharmaceutical agent, first pegfilgrastim followed by filgrastim.

On the first day of the study, a first blood draw of 130 mL will be performed which will be used to create standard PRP for laboratory testing and subjects will begin a filgrastim or pegfilgrastim dosage series. After the specified time (4 days for filgrastim and 7 days for pegfilgrastim), a second 130 mL of blood will be harvested and processed with the Arthrex Angel system to create M-PRP for laboratory testing. The standard PRP and M-PRP cellular content will be studied and quantified in vitro with cell counting, cell culturing and protein analysis. 8 weeks after the second blood harvest, the subjects will return for a third 130 mL of blood draw, followed by administration of a second mobilizing agent (pegfilgrastim or filgrastim). After the specified time (4 days for filgrastim and 7 days for pegfilgrastim), the patients will return for a fourth blood draw of 130mL. The sample will be processed with the Arthrex Angel system to create M-PRP for laboratory testing. The cellular content of the M-PRP product will be studied and quantified in vitro with cell counting, cell culturing and protein analysis. Thereafter, the cellular content of M-PRP product will be compared between filgrastim and pegfilgrastim mobilization agents.
PURPOSE:To obtain wood ash useful as an assistant for health promotion and beauty, by collecting winter bud of a broad-leaved deciduous tree and baking the bud after withering. CONSTITUTION:A winter bud of a broad-leaved deciduous tree of Fagus family, Ulmus family, etc., is used as a raw material for the objective ash. Before opening new bud and leaves by the catalytic action of a metal such as germanium induced by the spring sunlight radiated to the winter bud, the new bud protected with paraffin coating layer is collected and dried by withering. The dried bud is baked on an open pan or in a closed vessel at 250-450 deg.C to obtain a 1st stage ash, which is baked at 500-800 deg.C to provide a 2nd stage ash. The ash is pulverized to fine powder with a crusher to obtain the objective ash. The wood ash is administered twice a day at a dose of 30-50mg or applied to skin after diluting 40-60mg of the ash 2-10 times with an ointment or face lotion.
1,223,962. Preparing chlortetracycline bisulphate. DIAMOND SHAMROCK CORP. 26 Feb., 1969 [28 Feb., 1968], No. 10388/69. Heading C2A. Crystalline chlortetracycline bisulphate is prepared by slurrying chlortetracycline in tetrahydrofuran, adding sulphuric acid to the slurry to form a solution of the bisulphate, clarifying the solution, and crystallizing and recovering the required product. The sulphuric acid may be added as a mixture with further tetrahydrofuran. Crystallization may be initiated by seeding with crystals of chlortetracycline bisulphate or by addition of a non- solvent, e.g. C 1  to C 4  alkanols. The starting tetracycline is suitably prepared by treating the hydrochloride salt with alkali or nitrogenous base. A further yield of the bisulphate is obtained from the mother-liquor after crystallization by precipitation with a non- solvent.
BACKGROUND/AIMS: The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population.
METHODS: Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3-1.67) and high cutoffs (2.67-3.25) for ruling in and out AF were calculated.
RESULTS: At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3-1.67.
CONCLUSION: Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.
Cancer is a complex set of conditions which collectively comprise the second biggest cause of death in the western world. In addition, these diseases, along with their various treatments, are associated with significant illness, as well as a host of debilitating symptoms. Two very common problems are cancer fatigue, as well as metabolic changes which can cause much suffering in and of themselves. Patients with advanced cancers, as well as many patients undergoing surgery, radiation therapy as well as chemotherapy all complain of fatigue, to a greater or lesser extent. Many gain or lose weight, and develop associated metabolic changes in uninvolved body systems, which can cause a significant health burden on the patients, as well as the healthcare system as a whole.

Little is known about the mechanisms which underlie these symptoms. Various biologic processes have been implicated including inflammation and other changes in body metabolism. There is urgent need to better understand these processes, which cause so much suffering in cancer patients, so as to potentially develop more effective solutions.
Ropinirole Hydrochloride Tablets 

If you have Restless Legs Syndrome (RLS, also known as Ekbom Syndrome), read this side 

Read this information completely before you start taking ropinirole hydrochloride. Read the information each time you get more medicine. There may be new information. This leaflet provides a summary about ropinirole hydrochloride. It does not include everything there is to know about your medicine. This information should not take the place of discussions with your doctor about your medical condition or ropinirole hydrochloride.
PURPOSE: Spinal surgeries are a very painful procedure. New regional techniques for postoperative pain management are being considered. The present study aimed to evaluate the hypothesis that the ultrasound-guided erector spinae plane (ESP) block would lead to lower opioid consumption compared to the thoracolumbar interfascial plane (TLIP) block after lumbar disk surgery. The study's primary objective was to compare postoperative total opioid consumption, and the secondary objective was to assess postoperative pain scores.
METHODS: Sixty-eight patients who underwent elective lumbar disk surgery were randomly assigned to either the ESP block group or the TLIP block group. The current pain status of the patients in both the ESP and TLIP block groups was assessed using the Numerical Rating Scale (NRS) at specific time intervals (30 min, 1, 6, 12 and 24 h) during the postoperative period. The number of times patients administered a bolus dose of patient-controlled analgesia, (PCA) within the first 24 h was recorded.
RESULTS: In the ESP group, the total opioid consumption in terms of morphine equivalents was found to be significantly lower (ESP group: 7.7 ± 7.0; TLIP group: 13.0 ± 10.1; p < 0.05). The NRS scores were similar between the groups at 30 min, 1, 6, and 12 h, but at 24 h, they were significantly lower in the ESP group. Moreover, the groups had no significant difference regarding observed side effects.
CONCLUSION: This study demonstrated the analgesic efficacy of both techniques, revealing that the ESP block provides more effective analgesia in patients undergoing lumbar disk surgery.